Assessment of cytochrome P450 enzyme inhibition and inactivation in drug discovery and development

Current Topics in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 382-403

  Nettleton, David O ^a   Einolf, Heidi J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cyp; Cytochrome p450; Drug drug interaction; Inactivation; Inhibition; Time dependent inactivation

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; MIDAZOLAM; TESTOSTERONE;

ARTICLE; DATA ANALYSIS; DECISION MAKING; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INACTIVATION; DRUG INTERACTION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; IN VITRO STUDY; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOPHORE; PROTEIN FUNCTION; STEADY STATE; STRUCTURE ACTIVITY RELATION; STUDY DESIGN;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; ENZYME ACTIVATION; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 79551679016     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794480882     Document Type: Article

References (107)

1. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32, 1201-1208.
2. Krayenbuhl, J. C.; Vozeh, S.; Kondo-Oestreicher, M.; Dayer, P. Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol., 1999, 55, 559-565.
3. Po, A. L.; Zhang, W. Y. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet, 1998, 351, 1829-1830.
4. Prueksaritanont, T.; Ma, B.; Tang, C.; Meng, Y.; Assang, C.; Lu, P.; Reider, P. J.; Lin, J. H.; Baillie, T. A. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol., 1999, 47, 291-298.
5. FDA Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro, 1997.
6. FDA Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling, 2006.
7. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 2003, 31, 815-832.
8. Grimm, S. W.; Einolf, H. J.; Hall, S. D.; He, K.; Lim, H. K.; Ling, K. H.; Lu, C.; Nomeir, A. A.; Seibert, E.; Skordos, K. W.; Tonn, G. R.; Van Horn, R.; Wang, R. W.; Wong, Y. N.; Yang, T. J.; Obach, R. S. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos., 2009, 37, 1355-1370.
9. Parkinson, A. Biotransformation of xenobiotics. In Toxicology, The basic science of poisons, 5 ed.; Klaassen, C. D. Ed.; McGraw Hill: New York, 1996; pp 113-187.
10. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34, 83-448.
11. Brown, C. M.; Reisfeld, B.; Mayeno, A. N. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab. Rev., 2008, 40, 1-100.
12. Marathe, P. H. Rodrigues, A. D. In vivo animal models for investigating potential CYP3A-and PgP-mediated drug-drug interactions. Curr. Drug Metab., 2006, 7, 687-704.
13. Mandlekar, S. V.; Rose, A. V.; Cornelius, G.; Sleczka, B.; Caporuscio, C.; Wang, J.; Marathe, P. H. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica, 2007, 37, 923-942.
14. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol., 2008, 82, 667-715.
15. Ekins, S.; VandenBranden, M.; Ring, B. J.; Gillespie, J. S.; Yang, T. J.; Gelboin, H. V.; Wrighton, S. A. Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther., 1998, 286, 1253-1259.
16. Bogaards, J. J.; Hissink, E. M.; Briggs, M.; Weaver, R.; Jochemsen, R.; Jackson, P.; Bertrand, M.; van Bladeren, P. J. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur. J. Pharm. Sci., 2000, 12, 117-124.
17. Bernauer, U.; Garritsen, H.; Heinrich-Hirsch, B.; Gundert-Remy, U. Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. Regul. Toxicol. Pharmacol., 2003, 37, 318-327.
18. Cohen, L. H.; Remley, M. J.; Raunig, D.; Vaz, A. D. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos., 2003, 31, 1005-1015.
19. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem., 1997, 248, 188-190.
20. Crespi, C. L.; Miller, V. P.; Stresser, D. M. Design and application of fluorometric assays for human cytochrome P450 inhibition. Methods Enzymol., 2002, 357, 276-284.
21. Sekiguchi, N.; Higashida, A.; Kato, M.; Nabuchi, Y.; Mitsui, T.; Takanashi, K.; Aso, Y.; Ishigai, M. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab. Pharmacokinet., 2009, 24, 500-510.
22. Bachmann, K. A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr. Drug Metab., 2006, 7, 1-14.
23. Donato, M. T.; Castell, J. V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin. Pharmacokinet., 2003, 42, 153-178.
24. Renwick, A. B.; Lewis, D. F.; Fulford, S.; Surry, D.; Williams, B.; Worboys, P. D.; Cai, X.; Wang, R. W.; Price, R. J.; Lake, B. G.; Evans, D. C. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4. Xenobiotica, 2001, 31, 187-204.
25. Guengerich, F. P. Enzymatic oxidation of xenobiotic chemicals. Crit. Rev. Biochem. Mol. Biol., 1990, 25, 97-153.
26. Gao, F.; Johnson, D. L.; Ekins, S.; Janiszewski, J.; Kelly, K. G.; Meyer, R. D.; West, M. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J. Biomol. Screen., 2002, 7, 373-382.
27. Dierks, E. A.; Stams, K. R.; Lim, H. K.; Cornelius, G.; Zhang, H.; Ball, S. E. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos., 2001, 29, 23-29.
28. Bell, L.; Bickford, S.; Nguyen, P. H.; Wang, J.; He, T.; Zhang, B.; Friche, Y.; Zimmerlin, A.; Urban, L.; Bojanic, D. Evaluation of fluorescence-and mass spectrometry-based CYP inhibition assays for use in drug discovery. J. Biomol. Screen., 2008, 13, 343-353.
29. Fowler, S.; Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J., 2008, 10, 410-424.
30. Copeland, R. A. Enzymes: A practical introduction to structure, mechanism, and data analysis; John Wiley & Sons: New York, 2000.
31. Cornish-Bowden, A. Fundamentals of Enzymology; Portland Press: London, 1995.
32. Segal, I. H. Enzyme Kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems; John Wiley & Sons, Inc.: New York, 1975.
33. Foti, R. S.; Fisher, M. B. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab, Dispos., 2004, 32, 295-304.
34. Hickman, D.; Wang, J. P.; Wang, Y.; Unadkat, J. D. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos., 1998, 26, 207-215.
35. Busby, W. F. Jr.; Ackermann, J. M.; Crespi, C. L. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos., 1999, 27, 246-249.
36. Easterbrook, J.; Lu, C.; Sakai, Y.; Li, A. P. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDPdependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab. Dispos., 2001, 29, 141-144.
37. Zientek, M.; Miller, H.; Smith, D.; Dunklee, M. B.; Heinle, L.; Thurston, A.; Lee, C.; Hyland, R.; Fahmi, O.; Burdette, D. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J. Pharmacol. Toxicol. Methods, 2008, 58, 206-214.
38. Shou, M. Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. Methods Enzymol., 2002, 357, 261-276.
39. Galetin, A.; Clarke, S. E.; Houston, J. B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos., 2003, 31, 1108-1116.
40. Grime, K.; Riley, R. J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab., 2006, 7, 251-264.
41. Obach, R. S. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab. Dispos., 1996, 24, 1047-1049.
42. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K. Mechanismbased inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 2007, 35, 246-255.
43. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Houston, J. B.; Tremaine, L. M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther., 2005, 78, 582-592.
44. Bachmann, K. A., Lewis, J. D. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann. Pharmacother., 2005, 39, 1064-1072.
45. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Gaman, E. A.; Houston, J. B.; Tremaine, L. M. The utility of in vitro cytochrome p450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 2006, 316, 336-348.
46. Fahmi, O. A.; Hurst, S.; Plowchalk, D.; Cook, J.; Guo, F.; Youdim, K.; Dickins, M.; Phipps, A.; Darekar, A.; Hyland, R.; Obach, R. S. Comparison of different algorithms for predicting clinical drugdrug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab. Dispos., 2009, 37, 1658-1666.
47. Olkkola, K. T.; Backman, J. T.; Neuvonen, P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther., 1994, 55, 481-485.
48. Ito, K.; Brown, H. S.; Houston, J. B. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol., 2004, 57, 473-486.
49. Rowland, M.; Matin, S. B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm., 1973, 1, 553-567.
50. Hamelin, B. A.; Bouayad, A.; Methot, J.; Jobin, J.; Desgagnes, P.; Poirier, P.; Allaire, J.; Dumesnil, J.; Turgeon, J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther., 2000, 67, 466-477.
51. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta, 1999, 1461, 347-357.
52. Houston, J. B.; Galetin, A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab., 2008, 9, 940-951.
53. Youdim, K. A.; Zayed, A.; Dickins, M.; Phipps, A.; Griffiths, M.; Darekar, A.; Hyland, R.; Fahmi, O.; Hurst, S.; Plowchalk, D. R.; Cook, J.; Guo, F.; Obach, R. S. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br. J. Clin. Pharmacol., 2008, 65, 680-692.
54. Hinton, L. K.; Galetin, A.; Houston, J. B. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozildrug interactions. Pharm. Res., 2008, 25, 1063-1074.
55. Lu, C.; Berg, C.; Prakash, S. R.; Lee, F. W.; Balani, S. K. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab. Dispos., 2008, 36, 1261-1266.
56. Bachmann, K.; White, D.; Jauregui, L.; Schwartz, J. I.; Agrawal, N. G.; Mazenko, R.; Larson, P. J.; Porras, A. G. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J. Clin. Pharmacol., 2003, 43, 1082-1090.
57. Uttamsingh, V.; Lu, C.; Miwa, G.; Gan, L. S. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab. Dispos., 2005, 33, 1723-1728.
58. Wang, Y. H.; Jones, D. R.; Hall, S. D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos., 2004, 32, 259-266.
59. Ekins, S.; Berbaum, J.; Harrison, R. K. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab. Dispos., 2003, 31, 1077-1080.
60. Kontijevskis, A.; Komorowski, J.; Wikberg, J. E. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors. J. Chem. Inf. Model., 2008, 48, 1840-1850.
61. Dagliyan, O.; Kavakli, I. H.; Turkay, M. Classification of cytochrome P450 inhibitors with respect to binding free energy and pIC50 using common molecular descriptors. J. Chem. Inf. Model., 2009, 49, 2403-2411.
62. Appiah-Opong, R.; de, E. I; Commandeur, J. N.; Andarini, M.; Vermeulen, N. P. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur. J. Med. Chem., 2008, 43, 1621-1631.
63. Huang, S. M.; Strong, J. M.; Zhang, L.; Reynolds, K. S.; Nallani, S.; Temple, R.; Abraham, S.; Al Habet, S.; Baweja, R. K.; Burckart, G. J.; Chung, S.; Colangelo, P.; Frucht, D.; Green, M. D.; Hepp, P.; Karnaukhova, E.; Ko, H. S.; Lee, J. I.; Marroum, P. J.; Norden, J. M.; Qiu, W.; Rahman, A.; Sobel, S.; Stifano, T.; Thummel, K.; Wei, X. X.; Yasuda, S.; Zheng, J. H.; Zhao, H.; Lesko, L. J. New era in drug interaction evaluation: US food and drug administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48(6), 662-670.
64. Ripp, S. L.; Mills, J. B.; Fahmi, O. A.; Trevena, K. A.; Liras, J. L.; Maurer, T. S.; De Morais, S. M. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos., 2006, 34, 1742-1748.
65. Hollenberg, P. F.; Kent, U. M.; Bumpus, N. N. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol., 2008, 21, 189-205.
66. Franklin, M. R. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol., 1991, 206, 559-573.
67. Silverman, R. B. Mechanism-based enzyme inactivators. Methods Enzymol., 1995, 249, 240-283.
68. Lim, H. K.; Duczak, N. Jr.; Brougham, L.; Elliot, M.; Patel, K.; Chan, K. Automated screening with confirmation of mechanismbased inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos., 2005, 33, 1211-1219.
69. Kent, U. M.; Roberts, E. S.; Chun, J.; Hodge, K.; Juncaj, J.; Hollenberg, P. F. Inactivation of cytochrome P450 2E1 by tertbutylisothiocyanate. Chem. Res. Toxicol., 1998, 11, 1154-1161.
70. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J. C.; Clarke, S. E.; Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab., 2006, 7, 315-334.
71. Jones, D. R.; Gorski, J. C.; Hamman, M. A.; Mayhew, B. S.; Rider, S.; Hall, S. D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther., 1999, 290, 1116-1125.
72. Mayhew, B. S.; Jones, D. R.; Hall, S. D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos., 2000, 28, 1031-1037.
73. Venkatakrishnan, K.; Obach, R. S. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr. Drug Metab., 2007, 8, 449-462.
74. Yang, J.; Jamei, M.; Heydari, A.; Yeo, K. R.; de la, T. R.; Farre, M.; Tucker, G. T.; Rostami-Hodjegan, A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol., 2006, 20, 842-849.
75. Einolf, H. J. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica, 2007, 37, 1257-1294.
76. Kalgutkar, A. S.; Obach, R. S.; Maurer, T. S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab., 2007, 8, 407-447.
77. Riley, R. J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition. Expert. Opin. Drug Metab. Toxicol., 2007, 3, 51-66.
78. Fontana, E.; Dansette, P. M.; Poli, S. M. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab., 2005, 6, 413-454.
79. Correia, M. A. Ortiz de Montellano, P. R. Inhibition of Cytochrome P450 Enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry. 3 ed.; Ortiz de Montellano, P. R. Ed.; Kluwer Academic/ Plenum Publishers: New York, 2005; pp 247-322.
80. Racha, J. K.; Rettie, A. E.; Kunze, K. L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry, 1998, 37, 7407-7419.
81. Kunze, K. L.; Trager, W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol., 1993, 6, 649-656.
82. Wen, X.; Wang, J. S.; Backman, J. T.; Kivisto, K. T.; Neuvonen, P. J. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos., 2001, 29, 1359-1361.
83. Wang, J. S.; Neuvonen, M.; Wen, X.; Backman, J. T.; Neuvonen, P. J. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos., 2002, 30, 1352-1356.
84. Backman, J. T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther., 2002, 72, 685-691.
85. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46, 347-351.
86. Lilja, J. J.; Backman, J. T.; Neuvonen, P. J. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2005, 59, 433-439.
87. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 2004, 311, 228-236.
88. Ogilvie, B. W.; Zhang, D.; Li, W.; Rodrigues, A. D.; Gipson, A. E.; Holsapple, J.; Toren, P.; Parkinson, A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos., 2006, 34, 191-197.
89. Baer, B. R.; DeLisle, R. K.; Allen, A. Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem. Res. Toxicol., 2009, 22, 1298-1309.
90. Venkatakrishnan, K.; Obach, R. S.; Rostami-Hodjegan, A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica, 2007, 37, 1225-1256.
91. Ma, B.; Prueksaritanont, T.; Lin, J. H. Drug interactions with calcium channel blockers: possible involvement of metaboliteintermediate complexation with CYP3A. Drug Metab. Dispos., 2000, 28, 125-130.
92. Schlezinger, J. J.; White, R. D.; Stegeman, J. J. Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As. Mol. Pharmacol., 1999, 56, 588-597.
93. Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibitory effects of amiodarone and its Ndeethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol., 2000, 49, 244-253.
94. Ito, K.; Ogihara, K.; Kanamitsu, S.; Itoh, T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos., 2003, 31, 945-954.
95. Zhao, P.; Lee, C. A.; Kunze, K. L. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab. Dispos., 2007, 35, 704-712.
96. Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K. Risk assessment for drug-drug interaction caused by metabolismbased inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos., 2007, 35, 1232-1238.
97. Atkinson, A.; Kenny, J. R.; Grime, K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos., 2005, 33, 1637-1647.
98. Wen, X.; Wang, J. S.; Neuvonen, P. J.; Backman, J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol., 2002, 57, 799-804.
99. Ernest, C. S.; Hall, S. D.; Jones, D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther., 2005, 312, 583-591.
100. Soars, M. G.; Grime, K.; Riley, R. J. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica, 2006, 36, 287-299.
101. Greenblatt, D. J.; Von Moltke, L. L.; Harmatz, J. S.; Chen, G.; Weemhoff, J. L.; Jen, C.; Kelley, C. J.; LeDuc, B. W.; Zinny, M. A. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther., 2003, 74, 121-129.
102. Kato, M.; Chiba, K.; Horikawa, M.; Sugiyama, Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab. Pharmacokinet., 2005, 20, 236-243.
103. Galetin, A.; Burt, H.; Gibbons, L.; Houston, J. B. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos., 2006, 34, 166-175.
104. Yang, J.; Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab., 2008, 9, 384-394.
105. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drugdrug interactions: metabolic interaction in the liver. Pharmacol. Rev., 1998, 50, 387-412.
106. Kanamitsu, S.; Ito, K.; Green, C. E.; Tyson, C. A.; Shimada, N.; Sugiyama, Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 2000, 17, 419-426.
107. Yamano, K.; Yamamoto, K.; Katashima, M.; Kotaki, H.; Takedomi, S.; Matsuo, H.; Ohtani, H.; Sawada, Y.; Iga, T. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos., 2001, 29, 443-452.